Immune Checkpoint Inhibitor-Induced Lipodystrophy

Julia Riganti¹, Ana C Torre¹, Pietro Sollena², Dimitra Koumaki³, Azael Freites-Martinez⁴, Julie Delyon⁵, Antoine Communie⁶, Michela Starace^{7

8}, Luca Rapparini^{7

8}, Aimilios Lallas⁹, Dimitrios Mavroudis¹⁰, Devaux Suzanne¹¹, Luis D Mazzuoccolo¹, Mattheos Bobos¹², Vincent Sibaud¹³, Zoe Apalla^{14

15}

Affiliations

¹ Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
² Dipartimento di Scienze Mediche e Chirurgiche, Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
³ Dermatology Department, University Hospital of Heraklion, Heraklion, Crete, Greece.
⁴ Dermatology Department, Hospital Ruber Juan Bravo y Universidad Europea, Madrid, España.
⁵ Department of Dermato-oncology, AP-HP Saint Louis Hospital; Universite Paris Cite; INSERM U976, Paris, France.
⁶ Service de Dermatologie et Vénéréologie, CHU Angers, Angers, France.
⁷ Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
⁸ Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
⁹ First Dermatology Department, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
¹⁰ Department of Medical Oncology, University Hospital of Heraklion, Laboratory of Translational Oncology Medical School, University of Crete, Heraklion, Crete, Greece.
¹¹ Dermatology Department, Centre Hospitalier de la Côte Basque, Bayonne, France.
¹² Department of Biomedical Sciences, School of Health Sciences at the International Hellenic University, Thessaloniki, Greece.
¹³ Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France.
¹⁴ Second Dermatology Department, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
¹⁵ Dermatologia, Universita Cattolica del Sacro Cuore, Rome, Italy.

PMID: 40202750
PMCID: PMC11983295 (available on 2026-04-09)
DOI: 10.1001/jamadermatol.2025.0359

Immune Checkpoint Inhibitor-Induced Lipodystrophy

Julia Riganti et al. JAMA Dermatol. 2025.

. 2025 Jun 1;161(6):658-661.

doi: 10.1001/jamadermatol.2025.0359.

Authors

Affiliations

¹ Dermatology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
² Dipartimento di Scienze Mediche e Chirurgiche, Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
³ Dermatology Department, University Hospital of Heraklion, Heraklion, Crete, Greece.
⁴ Dermatology Department, Hospital Ruber Juan Bravo y Universidad Europea, Madrid, España.
⁵ Department of Dermato-oncology, AP-HP Saint Louis Hospital; Universite Paris Cite; INSERM U976, Paris, France.
⁶ Service de Dermatologie et Vénéréologie, CHU Angers, Angers, France.
⁷ Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
⁸ Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
⁹ First Dermatology Department, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
¹⁰ Department of Medical Oncology, University Hospital of Heraklion, Laboratory of Translational Oncology Medical School, University of Crete, Heraklion, Crete, Greece.
¹¹ Dermatology Department, Centre Hospitalier de la Côte Basque, Bayonne, France.
¹² Department of Biomedical Sciences, School of Health Sciences at the International Hellenic University, Thessaloniki, Greece.
¹³ Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France.
¹⁴ Second Dermatology Department, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.
¹⁵ Dermatologia, Universita Cattolica del Sacro Cuore, Rome, Italy.

PMID: 40202750
PMCID: PMC11983295 (available on 2026-04-09)
DOI: 10.1001/jamadermatol.2025.0359

No abstract available

Plain language summary

This case series describes lipodystrophy, a rare adverse event associated with immune checkpoint inhibitor therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Riganti reported personal fees from Jansen Laboratories, Raffo Laboratories, La Roche-Posay, Cerave, and Unilever. Dr Sibaud reported personal fees from Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, and Pierre Fabre during the conduct of the study and personal fees from AstraZeneca, Astellas, and L’Oréal outside the submitted work. No other disclosures were reported.

References

1. Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events—the EADV task force ‘Dermatology for Cancer Patients’ position statement. J Eur Acad Dermatol Venereol. 2022;36(3):332-350. doi: 10.1111/jdv.17855 - DOI - PubMed
1. Corvillo F, Abel BS, López-Lera A, et al. Characterization and clinical association of autoantibodies against perilipin 1 in patients with acquired generalized lipodystrophy. Diabetes. 2023;72(1):71-84. doi: 10.2337/db21-1086 - DOI - PMC - PubMed
1. Unal MC, Semiz GG, Ozdoğan O, et al. Nivolumab associated endocrine abnormalities: challenging cases from a reference clinic. Acta Endocrinol (Buchar). 2022;18(4):516-522. doi: 10.4183/aeb.2022.516 - DOI - PMC - PubMed
1. Haddad N, Vidal-Trecan T, Baroudjian B, et al. ; PATIO group . Acquired generalized lipodystrophy under immune checkpoint inhibition. Br J Dermatol. 2020;182(2):477-480. doi: 10.1111/bjd.18124 - DOI - PubMed
1. Bedrose S, Turin CG, Lavis VR, Sang TK, Thosani SN. A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma. AACE Clin Case Rep. 2020;6(1):e40-e45. doi: 10.4158/ACCR-2019-0234 - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immune Checkpoint Inhibitor-Induced Lipodystrophy

Affiliations

Immune Checkpoint Inhibitor-Induced Lipodystrophy

Authors

Affiliations

Plain language summary

Conflict of interest statement

References

LinkOut - more resources

Full Text Sources